Excellis Health Solutions - An NNIT Group Company’s Post

WHY DO DRUG PRICES VARY SO MUCH BETWEEN COUNTRIES? 🌍      Have you ever wondered why the same drug has different price levels in various countries? 📊    Drug pricing and reimbursement systems differ globally. Countries such as the United States and Germany operate with free drug pricing, while many EU countries use external price referencing (EPR) to stabilize costs. Countries that rely on EPR tend to have more controlled price variations compared to those using free pricing models.    Our analysis of 10 top-selling drugs highlights these pricing disparities, shedding light on the global drug pricing landscape 💊    🔗 Read our blog to discover how Ex-PRICE helps policymakers and companies make data-driven decisions: https://lnkd.in/dHVJRq7D  

Generic drugs play a crucial role in providing affordable medication options to patients worldwide. As we delve into the intricacies of generic drug markets in Europe and the United States, we’ll uncover fascinating insights into the pricing strategies, consumption patterns, and overall spending trends that shape these two distinct regions. Join me on this enlightening journey as we explore the similarities, differences, and unique characteristics of generic drug markets on both sides of the Atlantic. https://lnkd.in/dGFwCJG4

Generic drugs play a crucial role in providing affordable medication options to patients worldwide. As we delve into the intricacies of generic drug markets in Europe and the United States, we’ll uncover fascinating insights into the pricing strategies, consumption patterns, and overall spending trends that shape these two distinct regions. Join me on this enlightening journey as we explore the similarities, differences, and unique characteristics of generic drug markets on both sides of the Atlantic. https://lnkd.in/evdZRBPg

William Pay gives insights into the opportunities, regulatory pathways, and challenges of navigating the Chinese market. Hong Kong Winhealth Pharma Group

Generic drugs play a crucial role in providing affordable medication options to patients worldwide. As we delve into the intricacies of generic drug markets in Europe and the United States, we'll uncover fascinating insights into the pricing strategies, consumption patterns, and overall spending trends that shape these two distinct regions. Join me on this enlightening journey as we explore the similarities, differences, and unique characteristics of generic drug markets on both sides of the Atlantic. https://lnkd.in/evdZRBPg

Health Technology Assessment Unites Nordic Countries: Formation of Joint Nordic HTA-Bodies The formation of the Joint Nordic HTA-Bodies (JNHB) marks a significant advancement in health technology assessment (HTA) collaboration in the Nordic region, now including Denmark and Iceland alongside Finland, Norway, and Sweden. To celebrate, JNHB invited industry associations, decision-makers, and stakeholders to a launch event unveiling their new website, which provides detailed guidance for Health Technology Developers. Initially a grassroots initiative, FINOSE expanded and rebranded to JNHB, formalized through a Memorandum of Understanding signed by the Lægemiddelstyrelsen (Danish Medicines Agency), Finnish Medicines Agency Fimea - Lääkealan turvallisuus- ja kehittämiskeskus Fimea, Landspítali - The National University Hospital of Iceland, Norwegian Medical Products Agency, and Swedish The Dental and Pharmaceutical Benefits Agency, TLV. For more details please click the link! https://lnkd.in/eUKmdp_a #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Highly effective drugs to treat serious and complex #autoimmune conditions often come with extremely high price tags. CVS Caremark leveraged our size and scale to move the market toward biosimilars and fulfill our commitment to deliver savings without compromising care. In just three short weeks, our adalimumab biosimilar adoption outpaced the entire U.S. market’s for 2023. Read our latest article for insights and early results. And learn how our bold biosimilars strategy is redefining what’s possible. https://cvs.co/3WkiJu5

Join our live panel, on June 11, with biopharma and market access and communication experts from Cencora, on the impact of biosimilars in the U.S. market landscape. We will delve into how to overcome regulatory hurdles, fostering collaborations, and enhancing communication with stakeholders amidst dynamic market changes. Register now: https://lnkd.in/enR3NEEr #Biosimilars #Marketaccess

I am looking forward to speaking at DIA 2024 next week and interacting with the government and regulatory affairs community who will join me in California. I will be chairing two crucial sessions on significant topics: high-risk excipients and drug shortages. The workshop titled Quality in Focus: Diethylene and Ethylene Glycol Challenges on Tuesday, June 18 at 11:00 AM will delve into the critical aspects of FDA's guidance on DEG testing, including quality tools available from Pharmacopeias, including USP, for ensuring the quality of excipients. You can learn more about this topic in a recent piece I contributed to @The Medicine Maker: US Pharmacopeia Mission to Address DEG/EG Contamination https://lnkd.in/eWPk-Zkj  The Roundtable Discussion: Securing the Chain - US and EU Legislative Reforms and Regulatory Actions for Drug Shortage Mitigation will be on Wednesday, June 19 at 11:00 AM. We will discuss how the medicine supply chains are becoming increasingly complex, requiring innovative solutions to ensure the continuous supply of quality medicines. As a standard-setting organization, US Pharmacopeia supports this work by facilitating global information exchange and enabling manufacturers to focus on production while ensuring product quality, safety, and supply chain resiliency. If you want to learn more about the drug shortages issues, please check out USP's call to action and the USP Annual Drug Shortages Report at https://lnkd.in/ecu5rYM3 If you are attending DIA and have time to catch these sessions, I look forward to interacting with you. #DIA2024 #Pharma #DrugQuality #RegulatoryAffairs

📢 To reduce medicine shortages, a #CriticalMedicinesAct must be a top priority for the European Commission in its first 100 days. Long-term resilience in medicine supply requires market conditions for healthy competition and investment in sustainable supply chains. ⏰ It's time for a reform of European pharmaceutical markets to support robust, secure supply chains. A #CriticalMedicinesAct will help build a healthier, more resilient Europe. #EUCriticalHealth